BBD is focused on advancing biometrology, standards, and technologies to foster innovation and accelerate the translation and commercialization of emerging biotechnologies in support of the bioeconomy. Working across U.S. government agencies, industry, and other partners, our multi-disciplinary teams develop foundational measurement science and tools, data-driven standards, reference materials, reference data, and protocols by integrating state-of-the-art automation, analytical methods, and ML/AI as platforms for innovation and standardization. Our work supports various sectors of the bioeconomy, including clinical diagnostics, advanced therapies, agriculture, energy, industrial biotechnology, and production of new biomaterials. Click here for an overview video of the Division.
Rapid advances in the ability to genetically modify biological organisms have advanced a new engineering discipline, commonly referred to as synthetic biology. This approach seeks to harness the power of living systems for a variety of manufacturing applications, such as advanced therapeutics, sustainable fuels, chemical feedstocks, and advanced materials.
Advanced therapies are demonstrating promising clinical efficacy and could change the paradigm for treating a wide range of diseases and injuries. Clinical translation of this broad class of new therapeutics requires better defined and characterized products and more robust, reliable, and cost-effective manufacturing processes.
The conventional approach to medicine is rapidly changing to a data-driven strategy in which therapies are individually targeted to a patient based on genome, physiology, environment, or lifestyle. This approach is revolutionizing health care— especially in the treatment of cancer—but its success depends on using data from bioanalytical measurements with potential wide-ranging biases and uncertainties.
Microbial communities (microbiomes) abound everywhere, forming resilient ecological networks adapted to their environments. Research has connected the behavior of these cooperative communities to both beneficial and problematic outcomes in diverse biological systems including: human health, agricultural productivity, water and food safety, waste remediation, and infrastructure corrosion.
CRISPR Medicine News: Creating the common language of genome editing
Taking Measure Blog Post: NIST Gets Going With the Flow Cytometry Standards Consortium
NIST-FDA Workshop Report: Workshop on Standards for Pathogen Detection via Next-Generation Sequencing
Taking Measure Blog Post: The Rapid Microbial Testing Methods Consortium: Enabling Safe, Effective and Timely Advanced Therapies
Taking Measure Blog Post: Rewritten in Our DNA: Measurements for Genome Editing
Nature: The promise and challenge of therapeutic genome editing
Taking Measure Blog Post: Genome in a Bottle: Spelling Out DNA’s ‘Dark’ Sequences
Taking Measure Blog Post: Say Hello to Our Little Friends: Toward Microbial BiotheraPOOtics and Diagnostics